このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Multisensory Room Therapy for Stress and Sensory Regulation in Children With Autism and Their Caregivers

2026年11月13日 更新者:SERGIO MONTERO NAVARRO

Multidimensional Study of Child and Parental Stress in Autism Spectrum Disorder After a Multisensory Intervention: Biomarkers, Sensory Responses and Clinical Assessment. A Randomised Controlled Trial

The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).

Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.

Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.

Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.

Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.

Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.

研究の種類

介入

入学 (推定)

120

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年~12年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria (children):

  • Clinical diagnosis of autism spectrum disorder, support level 2 or 3 (DSM-5).
  • Age 3 to 12 years.
  • Attending and registered at the Centre de Teràpia Interfamiliar.
  • Stable therapeutic and pharmacological treatment during the study period.
  • Able to tolerate entering and remaining in the multisensory room.
  • Written informed consent from parents or legal guardians.

Exclusion Criteria (children):

  • Uncontrolled epilepsy.
  • Recent changes in medication.
  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the intervention.
  • Persistent refusal of, or inability to adapt to, the multisensory room.

Inclusion Criteria (caregivers):

  • Adult (18 years or older) main caregiver of an enrolled child.
  • Sufficient cognitive capacity to understand the informed consent.

Exclusion Criteria (caregivers):

  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the assessments.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Multisensory room therapy

Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples.

Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.

他の名前:
  • Snoezelen; Multisensory environment (MSE)
アクティブコンパレータ:Standard behavioural therapy

Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments.

45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)
時間枠:Baseline and week 8

Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome).

Baseline and week 8

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)
時間枠:Baseline and week 8

Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome).

Baseline and week 8
Change in emotional and behavioural problems (SENA, Global Problems Index)
時間枠:Baseline and week 8

Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: >70). Higher scores indicate more emotional and behavioural problems (worse outcome).

Baseline and week 8
Parenting stress (PSI-SF)
時間枠:Baseline and week 8

PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress.

Baseline and week 8
Child salivary cortisol (ng/mL)
時間枠:Baseline and before/after each session, weeks 1-8

ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

Baseline and before/after each session, weeks 1-8
Child salivary oxytocin (pg/mL)
時間枠:Baseline and before/after each session, weeks 1-8

ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

Baseline and before/after each session, weeks 1-8
Child salivary pro-inflammatory cytokines
時間枠:Baseline and before/after each session, weeks 1-8

Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA).

Baseline and before/after each session, weeks 1-8
Caregiver stress biomarkers - Salivary cortisol (ng/mL)
時間枠:Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - oxytocin (pg/mL)
時間枠:Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)
時間枠:Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - hair cortisol (pg/mg)
時間枠:Baseline and week 8
Baseline and week 8
In-session self-regulation (observational record)
時間枠:After each session, weeks 1-8

Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty.

After each session, weeks 1-8
Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device
時間枠:Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device
時間枠:Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Breathing rate (breaths per minute). BIOPAC MP36R device
時間枠:Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Skin temperature (ºC). BIOPAC MP36R device
時間枠:Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8

その他の成果指標

結果測定
メジャーの説明
時間枠
Adverse events
時間枠:Weeks 1-8

Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group.

Weeks 1-8

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月3日

一次修了 (推定)

2027年3月30日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2026年11月4日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CEEI26/863

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。